Skip to content

Intravenous remedial application of tranexamic acid enhanced recovery after surgery to reduce postoperative hidden hemorrhage and inflammatory reaction-a prospective randomized controlled trial

Intravenous remedial application of tranexamic acid enhanced recovery after surgery to reduce postoperative hidden hemorrhage and inflammatory reaction-a prospective randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16010188
Enrollment
Unknown
Registered
2016-12-19
Start date
2017-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip osteoarthritis and avascular necrosis of the femoral head, hip dysplasia,knee osteoarthritis,knee traumatic arthritis

Interventions

intravenous remedial group:intravenous remedial application of TXA after using TXA three times intravenously
control group:No more application of TXA after using TXA 3 times intravenously

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients following primary total hip/knee arthroplasty due to osteoarthritis, hip dysplasia and ischemic necrosis of the femoral head; 2. Patinets without preoperative platelet and coagulation function dysfunction; 3. Preoperative double lower limb venous color Doppler ultrasound was not abnormal; 4. voluntarily participated in clinical trials and signed informed consent, good compliance of patients.

Exclusion criteria

Exclusion criteria: (1) Patinets with history of venous thromboembolism, pulmonary embolism, cerebral infarction, coronary heart disease; (2) Patients with coagulation disorders; (3) Anticoagulant drugs are being used; (4) Administration of NSAID for less than 1 weeks; (5) TXA allergy; (6) Severe liver and renal insufficiency; (7) Patients with high risk of thrombosis, including atrial fibrillation, cardiac pacemaker, and stent implantation

Design outcomes

Primary

MeasureTime frame
Hidden blood loss;Inflammatory index;D-Dimer;Fibrin degradation products;

Secondary

MeasureTime frame
The drop of hemoglobin;Allogeneic blood transfusion rate;Total blood loss;VAS;Limb swelling ratio;Joint mobility;Postoperative hospital stay;adverse event rate;

Countries

China

Contacts

Public ContactFuxing Pei

West China Hospital, Sichuan University

peifuxing195112@163.com+86 18980601380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026